This company listing is no longer active
PA8 Stock Overview
A specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Paion AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.36 |
| 52 Week High | €8.96 |
| 52 Week Low | €0.22 |
| Beta | 1.68 |
| 11 Month Change | 0% |
| 3 Month Change | 4.35% |
| 1 Year Change | -94.90% |
| 33 Year Change | -98.54% |
| 5 Year Change | -98.41% |
| Change since IPO | -99.60% |
Recent News & Updates
Recent updates
Here's Why We're Not At All Concerned With Paion's (ETR:PA8) Cash Burn Situation
Nov 17
Results: Paion AG Beat Earnings Expectations And Analysts Now Have New Forecasts
Apr 03Paion AG's (ETR:PA8) Stock Has Fared Decently: Is the Market Following Strong Financials?
Feb 09
Did You Miss Paion's (ETR:PA8) 28% Share Price Gain?
Dec 15Shareholder Returns
| PA8 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.8% | -2.2% |
| 1Y | -94.9% | -14.4% | 13.3% |
Return vs Industry: PA8 underperformed the German Biotechs industry which returned -27.9% over the past year.
Return vs Market: PA8 underperformed the German Market which returned 0.1% over the past year.
Price Volatility
| PA8 volatility | |
|---|---|
| PA8 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PA8's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine PA8's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 64 | Tilmann Bur | www.paion.com |
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. The company’s lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults.
Paion AG Fundamentals Summary
| PA8 fundamental statistics | |
|---|---|
| Market cap | €2.57m |
| Earnings (TTM) | -€19.86m |
| Revenue (TTM) | €14.81m |
0.2x
P/S Ratio-0.1x
P/E RatioIs PA8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PA8 income statement (TTM) | |
|---|---|
| Revenue | €14.81m |
| Cost of Revenue | €6.35m |
| Gross Profit | €8.46m |
| Other Expenses | €28.32m |
| Earnings | -€19.86m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.78 |
| Gross Margin | 57.15% |
| Net Profit Margin | -134.12% |
| Debt/Equity Ratio | -675.5% |
How did PA8 perform over the long term?
See historical performance and comparison